Surgery for full- thickness macular holes with short-duration prone posturing: Results of a pilot study

Eye (Basingstoke)

Volumn 14, Issue 3, 2000, Pages 307-312

  Ellis, John D ^a   Malik, Tahira Y ^a   Taubert, Mark A K ^b   Barr, Andrew ^a   Baines, Paul S ^a  

^a NHS TAYSIDE   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Macular hole; Platelets; Posturing; Tamponade; Vitrectomy

Indexed keywords

THROMBOCYTE CONCENTRATE;

ADULT; AGED; ARTICLE; BODY POSTURE; CATARACT; CILIARY DISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; IDIOPATHIC DISEASE; MALE; METAMORPHOSIS; PILOT STUDY; QUALITY OF LIFE; RETINA MACULA HOLE; RETINA SURGERY; TREATMENT OUTCOME; VISION; VISUAL ACUITY; VITRECTOMY;

EID: 0033912334     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2000.78     Document Type: Article

References (43)

1. Smiddy WE, Pimentel S, Williams GA. Macular hole surgery without using adjunctive additives. Ophthalmic Surg Lasers 1997; 28: 713-7.
2. Goldbaum MH, McCuen BW, Hanneken AM, Burgess SK, Chen HH. Silicone oil tamponade to seal macular holes without position restrictions. Opthalmology 1998; 105: 2140-7; discussion 2147-8.
3. Tornambe PE, Poliner LS, Grote K. Macular hole surgery without face-down positioning: a pilot study. Retina 1997; 17: 179-85.
4. Kelly NE, Wendel RT. Vitreous surgery for idiopathic macular holes: results of a pilot study. Arch Ophthalmol 1991; 109: 654-9.
5. Poliner LS, Tornambe PE. Retinal pigment epitheliopathy after macular hole surgery. Ophthalmology 1992; 99: 1671-7.
6. Wendel RT, Patel AC, Kelly NE, Salzano TC, Wells JW, Novack GD. Vitreous surgery for macular holes. Ophthalmology 1993; 100: 1671-6.
7. Orellana J, Lieberman RM. Stage II macular hole surgery. Br J Ophthalmol 1993; 77: 555-8.
8. Ruby AJ, Williams DF, Grand MG, Thomas MA, Meredith TA, Boniuk 1, Pars plana vitrectomy for treatment of stage 2 macular holes. Arch Ophthalmol 1994; 112: 359-64.
9. Gaudric A, Massin P, Paques M, Santiago PY, Guez JE, Le Gargasson JF, Autologous platelet concentrate for the treatment of full-thickness macular holes. Graefes Arch Clin Exp Ophthalmol 1995; 233: 549-54.
10. Korobelnik JF, Hannouche D, Belayachi N, Branger M, Guez JE, Hoang-Xuan T. Autologous platelet concentrate as an adjunct in macular hole healing: a pilot study. Ophthalmology 1996; 103: 590-4.
11. Gaudric A, Paques M, Massin P, Santiago P, Dosquet C. Use of autologous platelet concentrate in macular hole surgery: report of 77 cases. Dev Ophthalmol 1997; 29: 30-5.
12. Wells JA, Gregor ZJ. Surgical treatment of full-thickness macular holes using autologous serum. Eye 1996; 10: 593-9.
13. Olsen TW, Sternberg P Jr, Capone A Jr, Martin DF, Lim JI, Grossniklaus HE, Macular hole surgery using thrombinactivated fibrinogen and selective removal of the internal limiting membrane. Retina 1998; 18: 322-9.
14. Pearce IA, Branley M, Groenewald C, McGalliard J, Wong D. Visual function and patient satisfaction after macular hole surgery. Eye 1998; 12: 651-8.
15. Glaser BM, Michels RG, Kuppermann BD, Sjaarda RN, Pena RA. Transforming growth factor-132 for the treatment of full thickness macular holes. Ophthalmology 1992; 99: 1162-74.
16. Lansing MB, Glaser BM, Liss H, Hanham A, Thompson JT, Sjaarda RN, Gordon A. The effect of pars plana vitrectomy and transforming growth factor-beta 2 without epiretinal membrane peeling on full-thickness macular holes. Ophthalmology 1993; 100: 868-71.
17. Minihan M, Goggin M, Cleary PE. Surgical management of macular holes: results using gas tamponade alone, or in combination with autologous platelet concentrate, or transforming growth factor beta 2. Br J Ophthalmol 1997; 81: 1073-9.
18. Thompson JT, Smiddy WE, Glaser BM, Sjaarda RN, Flynn HW. Intraocular tamponade duration and success of macular hole surgery. Retina 1996; 16: 373-82.
19. Storz Ophthalmics. The days following macular hole surgery. Face down posturing, SPA-5618REV. 7/96. 3365 Tree Court Industrial Blvd, St Louis, MO, USA, 1996.
20. Ezra E, Arden GB, Riordan-Eva P, Aylward GW, Gregor ZJ. Visual field loss following vitrectomy for stage 2 and 3 macular holes. Br J Ophthalmol 1996; 80: 519-25.
21. Gass JDM. Idiopathic senile macular hole: its stages and pathogenesis. Arch Ophthalmol 1988; 106: 629-39.
22. Gass JDM. Reappraisal of biomicroscopic classification of stages of development of a macular hole. Am J Ophthalmol 1995; 119: 752-9.
23. Watzke RC, Allen L. Subjective slit beam sign for macular disease. Am J Ophthalmol 1969; 68: 449.
24. Ducker JS, Wendel R, Patel AC, Puliafito CA. Late re-opening of macular holes after initially successful treatment with vitreous surgery. Ophthalmology 1994; 101: 1373-8.
25. Thompson JT, Glaser BM, Sjaarda RN, Murphy RP. Progression of nuclear sclerosis and long-term visual results of vitrectomy with transforming growth factor beta-2 for macular holes. Am J Ophthalmol 1995; 119: 48-54.
26. Paques M, Massin P, Santiago PY, Spielmann AC, Le Gargasson JF, Gaudric A. Late reopening of successfully treated macular holes. Br J Ophthalmol 1997; 81: 658-62.
27. Yeo JH, Sadeghi J, Green R, Glaser BM. Intravenous fibronectin and platelet-derived growth factor. Arch Ophthalmol 1986; 104: 417-21.
28. Ryan EH, Gilbert HD. Results of surgical treatment of recent onset full-thickness idiopathic macular holes. Arch Ophthalmol 1995; 113: 822-3.
29. Smiddy WE, Glaser BM, Thompson JT, Sjaarda RN, Flynn HW Jr, Hanham A, Transforming growth factor beta-2 significantly enhances the ability to flatten the rim of subretinal fluid surrounding macular holes: preliminary anatomic results of a multicenter prospective randomized study. Retina 1993; 13: 296-301.
30. Paques M, Chastang C, Mathis A, Sahel J, Massin P, Dosquet C, Effect of autologous platelet concentrate in surgery for idiopathic macular hole: results of a multicenter, doublemasked, randomized trial. Platelets in Macular Hole Surgery Group. Ophthalmology 1999; 106: 932-8.
31. Roth DB, Smiddy WE, Feuer W. Vitreous surgery for chronic macular holes. Ophthalmology 1997; 104: 2047-52.
32. Thompson JT, Sjaarda RN, Lansing MB. The results of vitreous surgery for chronic macular holes. Retina 1997; 17: 493-501.
33. Madreperla SA, Geiger GL, Funata M, de la Cruz Z, Green WR. Clinicopathologic correlation of a macular hole treated by cortical vitreous peeling and gas tamponade. Ophthalmology 1994; 101: 682-6.
34. Funata MT, Wendel RT, De La Cruz Z, Green WR. Clinicopathologic study of bilateral macular holes treated with pars plana vitrectomy and gas tamponade. Retina 1992; 12: 289-98.
35. Guyer DR, Green WR, de Bustros S, Fine SL. Histopathologic features of idiopathic macular holes and cysts. Ophthalmology 1990; 97: 1045-51.
36. Ezra E, Munro PM, Charteris DG, Aylward WG, Luthert PJ, Gregor ZJ. Macular hole opercula: ultrastructural features and clinicopathological correlation. Arch Ophthalmol 1997; 115: 1381-7.
37. Wong D, Groenewald C. Macular hole surgery. Continuing Med Educ J 1997; 1: 49-52.
38. Thompson JT, Glaser BM, Sjaarda RN, Murphy RP, Hanham A. Effects of intraocular bubble duration in the treatment of macular holes by vitrectomy and transforming growth factor-beta 2. Ophthalmology 1994; 101: 1195-200.
39. Schultz KF, Chalmers I, Hayes RJ, Altman DG. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408-12.
40. Boldt HC, Munden PM, Folk JC, Mehaffey MG. Visual field defects after macular hole surgery. Am J Ophthalmol 1996; 122: 371-81.
41. Paques M, Massin P, Santiago PY, Spielman AC, Gaudric A. Visual field loss after vitrectomy for full-thickness macular holes. Am J Ophthalmol 1997; 124: 88-94.
42. Ezra E, Arden GB, Riordan-Eva P, Aylward GW, Gregor ZJ. Visual field loss following vitrectomy for stage 2 and 3 macular holes. Br J Ophthalmol 1996; 80: 519-25.
43. Welch JC. Dehydration injury as a possible cause of visual field defect after pars plana vitrectomy for macular hole. Am J Ophthalmol 1997; 124: 698-9.